Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-08-28
2007-08-28
Chan, Christina (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388200, C530S388730
Reexamination Certificate
active
10469304
ABSTRACT:
This invention provides an anti-HLA-DR monoclonal antibody. This invention relates to an antibody binding to HLA-DR or a functional fragment thereof having (a) life-extending effects in nonhuman animals bearing HLA-DR-expressing cancer cells and (b) activity of suppressing immune responses lower than that of L243, or an antibody binding to HLA-DR or a functional fragment thereof exhibiting immunosuppressive activity equivalent to or higher than that of the mouse anti-HLA-DR monoclonal antibody L243 (ATCC HB-55).
REFERENCES:
patent: 6416958 (2002-07-01), Vidovic et al.
patent: 2001/0053360 (2001-12-01), Vidovic et al.
patent: WO94/29351 (1994-12-01), None
patent: WO96/17874 (1996-06-01), None
patent: WO 01/87337 (2001-11-01), None
patent: WO 01/87338 (2001-11-01), None
patent: WO 02/088186 (2002-11-01), None
S. A. Kostelny et al., “Humanization and Characterization of the ANTI-HLA-DR Antibody 1D10”,Int. J. Cancer, Aug. 2001, vol. 93, No. 4, pp. 556-565.
H. L. Niman et al., “Generation of Protein-Reactive Antibodies by Short Peptides is an Event of High Frequency: Implications for the Structural basis of Immune Recognition”,Proc. Natl. Acad. Sci. USA, Aug. 1983, vol. 80, No. 16, pp. 4949-4953.
R. G. Ulrich et al., “Immune Recognition of Human Major Histocompatibility Antigens: Localization by a Comprehensive Synthetic Strategy of the Continuous Antigenic sites in the First Domain of HLA-DR2 β Chain”,Eur. J. Immunol., 1987, vol. 17, No. 4, pp. 497-502.
Johannes Stöckel et al., “Refolding of Human Class II Major Histocompatibility Complex Molecules Isolated fromEscherichia coli”The Journal of Biological Chemistry, vol. 269, No. 47, Nov. 1994, pp. 29571-29578.
C.B. Lock et al., “MHC class II sequences of an HLA-DR2 narcoleptic”, Immunogenetics 27: pp. 449-455, 1988.
Peter McLaughlin et al., “Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four Dose Treatment Program”, Journal of Clinical Oncology, vol. 16, No. 8 (Aug.), 1998: pp. 2825-2833.
B. Colffier et al., “Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing of Refractory Aggressive Lymphoma: A Multicenter Phase II Study”, Blood, vol. 92, No. 6, 1998, pp. 1927-1932.
Constantin N. Baxevanis et al., “Genetic Control of T-Cell Proliferative Responses to Poly (Glu40Ala60) and Poly (Glu51Lys34Tyr15): Subregion-Specific Inhibition of the Responses with Monoclonal la Antibodies.” Immunogenetics 11, 1980, pp. 617-628.
James T. Rosenbaum et al., “In Vivo Effects of Antibodies to Immune Response Gene Products I. Haplotype-specific Suppression of Humoral Immune Responses with a Monoclonal Anti-I-A”, J. Exp. Med., vol. 154, 1981, pp. 1694-1702.
Matthew K. Waldor et al., “In vivo therapy with monoclonal anti-I-A Antibody suppresses immune responses to acetylcholine receptor”, Proc. Natl. Acad. Sci. USA, vol. 80, (1983), pp. 2713-2717.
Margreet Jonker et al., “Successful Treatment of EAE in Rhesus Monkeys with MHC Class II Specific Monoclonal Antibodies”, Journal of Autoimmunity (1988), 1, pp. 399-414.
H.P.J.D. Stevens et al., “In Vivo Immunosuppressive Effects of Monoclonal Antibodies Specific for CD3+, CD4+, CD8+, and MHC Class II Positive Cells”, Transplantation Proceedings, vol. 22, No. 4, 1990, pp. 1783-1784.
R. Billing et al., “Prolongation of Skin Allograft Survival in Monkeys Treated with Anti-la and Anti-Blast/Monocyte Monoclonal Antibodies”, Transplantation Proceedings, vol. XV, No. 1, (1983), pp. 649-650.
M. Jonker et al., “Complications of Monoclonal Antibody (MAb) Therapy: The Importance of Primate Studies”, Transplantation Proceedings, vol. 23, No. 1, (1991), pp. 264-265.
Sheri A. Kostelny et al., “Humanization and Characterization of the ANTI-HLA-DR Antibody 1D10”, Int. J. Cancer, 93, (2001), pp. 556-565.
Supplementary Partial European Search Report of EP 02 80 1565.
Alberto Chersi et al., “Immunologic and Funcitonal Characterization of ANTI-HLA-DR Rabbit Antibodies Induced by Synthetic Peptides”, Molecular Immunology, vol. 21, No. 10, pp. 847-852, 1984.
R.J.T. Hancock et al., “MicroElisa assays of anti-HLA activity and isotype of human monoclonal antibodies”, Tissue Antigens (1989), 33, pp. 437-444.
D. Löffler et al., “Recognition of HLA-DR1/DRB1 *0101 molecules presenting HLA-A2 derived peptides by a human recombinant antibody, Fab-4 A1”, Erop. J. Immunogenet., vol. 25, 1998, pp. 339-347.
Kataoka Shiro
Tawara Tomonori
Chan Christina
Foley & Lardner LLP
Kirin Beer Kabushiki Kaisha
VanderVegt F. Pierre
LandOfFree
Anti-HLA-DR antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-HLA-DR antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-HLA-DR antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3836590